CSIMarket
Company Name or Ticker Symbol
Search for other Categories
 


Enanta Pharmaceuticals Inc  (ENTA)
Other Ticker:  
 
 

ENTA's Revenue Growth by Quarter and Year

Enanta Pharmaceuticals Inc's Revenue results by quarter and year




ENTA Revenue (in millions $) FY 2019 FY 2018 FY 2017 FY 2016
IV Quarter September - 67.21 75.93 12.84
III Quarter June - 57.26 7.51 13.98
II Quarter March - 44.05 8.96 13.00
I Quarter December 69.89 38.11 10.42 48.45
FY   69.89 206.63 102.82 88.27



ENTA Revenue first quarter 2019 Y/Y Growth Comment
Enanta Pharmaceuticals Inc reported Revenue surge of 83.38% year on year in the first quarter, to $ 69.89 millions, this is lower than Enanta Pharmaceuticals Inc's recent average Revenue surge of 317.64%.

Looking into first quarter results within Major Pharmaceutical Preparations industry 116 other companies have achieved higher Revenue growth. While Enanta Pharmaceuticals Inc' s Revenue jump of 83.38% ranks overall at the positon no. 1534 in the first quarter.




ENTA Revenue ( Y/Y Growth %) 2019
2018 2017 2016
IV Quarter September - -11.48 % 491.36 % -10.96 %
III Quarter June - 662.45 % -46.28 % 20.52 %
II Quarter March - 391.63 % -31.08 % -77.34 %
I Quarter December 83.38 % 265.74 % -78.49 % -37.48 %
FY   - 100.96 % 16.48 % -

Financial Statements
Enanta Pharmaceuticals Inc's first quarter 2019 Revenue $ 69.89 millions ENTA's Income Statement
Enanta Pharmaceuticals Inc's first quarter 2018 Revenue $ 38.11 millions Quarterly ENTA's Income Statement
New: More ENTA's historic Revenue Growth >>


ENTA Revenue (Quarter on Quarter Growth %)

2019
2018 2017 2016
IV Quarter September - 17.38 % 911.05 % -8.15 %
III Quarter June - 29.99 % -16.18 % 7.54 %
II Quarter March - 15.59 % -14.01 % -73.17 %
I Quarter December 3.98 % -49.81 % -18.85 % 235.99 %
FY (Year on Year)   - 100.96 % 16.48 % -




Revenue first quarter 2019 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #117
Healthcare Sector #301
Overall #1534

Revenue Y/Y Growth Statistics
High Average Low
2838.87 % 317.64 % -96.94 %
(Dec 31 2014)   (Dec 31 2013)
Revenue first quarter 2019 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #117
Healthcare Sector #301
Overall #1534
Revenue Y/Y Growth Statistics
High Average Low
2838.87 % 317.64 % -96.94 %
(Dec 31 2014)   (Dec 31 2013)

Revenue by Quarter for the Fiscal Years 2016, 2017, 2018, 2019

Enanta Pharmaceuticals Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
2838.87 % 317.64 % -96.94 %
(Dec 31 2014)  


ENTA's I. Quarter Q/Q Revenue Comment
Enanta Pharmaceuticals Inc achieved in the I. Quarter 2019 below company average Revenue growth of 3.98% quarter on quarter, to $ 69.89 millions.

Even if the I. Quarter 2019 results were lower than the regular , that was still encouraging story, as the I. Quarter expension, eclipses the -49.81% Revenue surge in the I. Quarter 2018

Within Major Pharmaceutical Preparations industry 116 other companies have achieved higher Revenue quarter on quarter growth. While Enanta Pharmaceuticals Inc's Revenue growth quarter on quarter, overall rank is 1534.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #117
Healthcare Sector #301
Overall #1534
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #117
Healthcare Sector #301
Overall #1534
Revenue Q/Q Growth Statistics
High Average Low
2838.87 % 317.64 % -96.94 %
(Dec 31 2014)  


ENTA's I. Quarter Q/Q Revenue Comment
Enanta Pharmaceuticals Inc achieved in the I. Quarter 2019 below company average Revenue growth of 3.98% quarter on quarter, to $ 69.89 millions.

I. Quarter 2019 Enanta Pharmaceuticals Inc's Revenue quarter on quarter growth were paradoxical, although lower than the average, yet it presents absolute recovery relative to the -49.81% in the I. Quarter 2018 Maja Olofsson, market advisor allocated in Stockholm mentioned.

Within Major Pharmaceutical Preparations industry 116 other companies have achieved higher Revenue quarter on quarter growth. While Enanta Pharmaceuticals Inc's Revenue growth quarter on quarter, overall rank is 1534.


Enanta Pharmaceuticals Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2018)
12 Months Ending
(Sep 30 2018)
12 Months Ending
(Jun 30 2018)
12 Months Ending
(Mar 31 2018)
12 Months Ending
(Dec 31 2017)
Cumulative Revenue 12 Months Ending $ 31.78 $ 206.63 $ 215.35 $ 165.60 $ 130.51
Y / Y Revenue Growth (TTM) -75.65 % 100.97 % 442.05 % 258.47 % 159.77 %
Year on Year Revenue Growth Overall Ranking # 469 # 3194 # 50 # 98 # 129
Seqeuential Revenue Change (TTM) 1.4907383891558E+17 % -4.05 % 30.04 % 26.89 % 26.93 %
Seq. Revenue Growth (TTM) Overall Ranking # 2 # 3470 # 159 # 172 # 371




Cumulative Revenue growth Comment
For the 12 months ended Dec 31 2018 Enanta Pharmaceuticals Inc reported a sharp drop in Revenue by -75.65% year on year, to $32 millions, compare to the 100.97% growth at Sep 30 2018.

In the Healthcare sector 44 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 469, from total ranking in previous quarter at 3194.

Revenue TTM Q/Q Growth Statistics
High Average Low
1.0E+17 %
7.4536919457788E+15 %
-100 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 1
Healthcare Sector # 45
Overall # 469

Revenue TTM Y/Y Growth Statistics
High Average Low
442.05 %
85.33 %
-100 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 1
Sector # 1
S&P 500 # 2
Cumulative Revenue growth Comment
For the 12 months ended Dec 31 2018 Enanta Pharmaceuticals Inc reported a sharp drop in Revenue by -75.65% year on year, to $32 millions, compare to the 100.97% growth at Sep 30 2018.

In the Healthcare sector 44 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 469, from total ranking in previous quarter at 3194.

Revenue TTM Q/Q Growth Statistics
High Average Low
1.0E+17 %
7.4536919457788E+15 %
-100 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 1
Healthcare Sector # 45
Overall # 469

Revenue TTM Y/Y Growth Statistics
High Average Low
442.05 %
85.33 %
-100 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 1
Sector # 1
S&P 500 # 2




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ENTA's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for ENTA's Competitors
Revenue Growth for Enanta Pharmaceuticals Inc's Suppliers
Revenue Growth for ENTA's Customers

You may also want to know
ENTA's Annual Growth Rates ENTA's Profitability Ratios ENTA's Asset Turnover Ratio ENTA's Dividend Growth
ENTA's Roe ENTA's Valuation Ratios ENTA's Financial Strength Ratios ENTA's Dividend Payout Ratio
ENTA's Roa ENTA's Inventory Turnover Ratio ENTA's Growth Rates ENTA's Dividend Comparisons



Companies with similar Revenue sharp drop for the quarter ending Dec 31 2018 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2018
Myokardia Inc  138.47 %$ 138.471 millions
Medovex Corp.  136.52 %$ 136.524 millions
Idera Pharmaceuticals, Inc.  135.26 %$ 135.260 millions
Reflect Scientific Inc  132.89 %$ 132.893 millions
Cerecor Inc.  123.15 %$ 123.148 millions
Amicus Therapeutics, Inc.  121.63 %$ 121.631 millions
Transenterix Inc.  121.42 %$ 121.424 millions
Davita Inc.  115.44 %$ 115.435 millions
Teladoc Health, Inc.  113.97 %$ 113.966 millions
Universal Health Services Inc  109.74 %$ 109.737 millions
Heron Therapeutics, Inc.  102.28 %$ 102.279 millions
Celsion Corp  100.00 %$ 100.000 millions
Innovus Pharmaceuticals, Inc.  99.76 %$ 99.757 millions
Neos Therapeutics, Inc.  97.68 %$ 97.676 millions
Array Biopharma Inc  95.53 %$ 95.530 millions
Sarepta Therapeutics, Inc.  95.52 %$ 95.524 millions
Immune Design Corp.  93.40 %$ 93.402 millions
Vivus Inc  92.69 %$ 92.689 millions
Exelixis, Inc.  91.53 %$ 91.531 millions
Caredx, Inc.  88.03 %$ 88.027 millions
Catasys, Inc.  85.30 %$ 85.305 millions
Wave Life Sciences Ltd.  84.69 %$ 84.694 millions
Dicerna Pharmaceuticals Inc  84.20 %$ 84.203 millions
Enanta Pharmaceuticals Inc  83.38 %$ 83.385 millions
Precision Optics Corporation, Inc.  81.83 %$ 81.828 millions
Chf Solutions, Inc.  80.39 %$ 80.385 millions
Immunomedics Inc  80.23 %$ 80.231 millions
Invitae Corp  78.57 %$ 78.574 millions
Clovis Oncology, Inc.  78.12 %$ 78.116 millions
Spark Therapeutics, Inc.  77.60 %$ 77.596 millions


             
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

IPDN's Profile

Stock Price

IPDN's Financials

Business Description

Fundamentals

Charts & Quotes

IPDN's News

Suppliers

IPDN's Competitors

Customers & Markets

Economic Indicators

IPDN's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2019 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday Data provided by Barchart and subject to terms of use. To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Stock Price, historical and current end-of-day data provided by eoddata. Intraday data delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Barchart and Eoddata. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071